Perioperative Outcomes and Pathological Response After Neoadjuvant Nivolumab Plus Platinum Chemotherapy in Clinically Node-Negative Non-Small Cell Lung Cancer. (PubMed, Ann Surg Oncol) - Sep 15, 2026 - "In patients with resectable cN0 NSCLC, nivolumab-based neoadjuvant chemoimmunotherapy was associated with perioperative outcomes and pCR rates similar to those observed in patients with cN1-2. These findings suggest that this regimen may represent a treatment option for patients with cN0, with careful attention to irAEs and disease progression."
Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|
|
Hana Oiki; Hironori Tenpaku; Hirotsugu Notsuda; Junichi Soh; Kei Namba; Kentaro Minegishi; Kotaro Nomura; Makoto Endo; Marina Nakatsuka; Masahiro Tsuboi; Masayuki Tanahashi; Mototsugu Shimokawa; Ryuji Nakamura; Satoshi Takamori; Shinkichi Takamori; Shinya Katsumata; Shinya Tane; Shuta Ohara; Takuya Watanabe; Yasuhisa Ohde
|